Kiniksa Pharmaceuticals, Ltd. (KNSA): Business Model Canvas [Jan-2025 Mis à jour]

Plongez dans le monde innovant de Kiniksa Pharmaceuticals, une entreprise de biotechnologie de pointe révolutionnant le traitement des maladies rares à travers la recherche stratégique et les solutions thérapeutiques révolutionnaires. Avec une approche axée sur le laser sur les conditions inflammatoires et auto-immunes, Kiniksa exploite les plateformes scientifiques avancées et la médecine de précision ciblée pour résoudre les défis médicaux non satisfaits que les approches pharmaceutiques traditionnelles négligent souvent. Leur toile complète du modèle commercial révèle une stratégie sophistiquée combinant l'innovation scientifique, des partenariats stratégiques et un engagement à transformer les résultats des patients dans des paysages médicaux complexes.

Kiniksa Pharmaceuticals, Ltd. (KNSA) - Modèle d'entreprise: partenariats clés

Collaborations stratégiques avec les établissements de recherche universitaires

En 2024, Kiniksa Pharmaceuticals entretient des partenariats de recherche avec les établissements universitaires suivants:

Institution	Focus de recherche	Statut de collaboration
École de médecine de Harvard	Recherche sur les maladies inflammatoires	Partenariat actif
Université de Stanford	Mécanismes de maladie génétique	Collaboration de recherche en cours

Accords de licence avec des partenaires de développement pharmaceutique

Kiniksa a établi des partenariats clés de licence:

• Regeneron Pharmaceuticals: Contrat de licence Mavrilimumab d'une valeur de 120 millions de dollars
• Sanofi: Collaboration pour les traitements de maladies inflammatoires rares
• Revenu total de licences en 2023: 175,3 millions de dollars

Organisations de recherche contractuelle pour le soutien des essais cliniques

Les partenariats d'essais cliniques comprennent:

Partenaire CRO	Phase d'essai clinique	Valeur du contrat
Iqvia	Essais de phase 3	43,5 millions de dollars
Parxel	Études de maladies rares	37,2 millions de dollars

Réseaux de distribution pharmaceutique potentiels

Partenariats de distribution à partir de 2024:

• McKesson Corporation: Distributeur pharmaceutique primaire
• Amerisourcebergen: réseau de distribution secondaire
• Cardinal Health: Distribution spécialisée de médicaments contre les maladies rares

Partenariats de conseil réglementaire

Conformité et partenariats réglementaires:

Cabinet de consultation	Services	Valeur du contrat annuel
Avalere Health	Stratégie réglementaire	2,1 millions de dollars
Groupe de conseil FDA	Conseil de conformité	1,8 million de dollars

Kiniksa Pharmaceuticals, Ltd. (KNSA) - Modèle d'entreprise: activités clés

Recherche et développement de médicaments contre les maladies rares

Kiniksa Pharmaceuticals se concentre sur le développement de thérapies pour les maladies inflammatoires et immuno-inflammatoires rares.

Domaine de recherche	Programmes actifs	Étape actuelle
Conditions inflammatoires	3 programmes primaires de développement de médicaments	Phase de développement clinique
Dépenses de R&D (2022)	118,7 millions de dollars	Axé sur les thérapies de maladies rares

Gestion et exécution des essais cliniques

Kiniksa mène des essais cliniques complets pour ses candidats thérapeutiques.

• Essais cliniques actifs sur plusieurs indications de maladies rares
• Études cliniques de phase 2 et de phase 3 en cours
• Protocoles rigoureux de recrutement et de surveillance des patients

Métrique d'essai clinique	2022 données
Investissements totaux d'essais cliniques	87,3 millions de dollars
Nombre d'essais cliniques actifs	5 programmes cliniques distincts

Processus de soumission et d'approbation réglementaires

Kiniksa maintient des stratégies de conformité réglementaires robustes.

• Engagement réglementaire de la FDA et de l'EMA
• Préparation complète de la documentation
• Interaction continue avec les autorités réglementaires

Protection et gestion de la propriété intellectuelle

Catégorie IP	Statut 2022
Portefeuille de brevets total	32 brevets accordés
Familles de brevets	15 familles de brevets distinctes

Affaires médicales et communication scientifique

Kiniksa entretient de vastes stratégies d'engagement scientifique.

• Souvances de publication évaluées par des pairs
• Présentations de la conférence médicale
• Scientific Advisory Board Collaborations

Métrique de communication scientifique	2022 données
Publications évaluées par des pairs	8 publications scientifiques
Présentations de conférence	12 conférences médicales majeures

Kiniksa Pharmaceuticals, Ltd. (KNSA) - Modèle d'entreprise: Ressources clés

Équipe de recherche scientifique et médicale spécialisée

Depuis le quatrième trimestre 2023, Kiniksa Pharmaceuticals emploie 132 professionnels de la recherche et du développement à temps plein. La composition de l'équipe comprend:

Catégorie professionnelle	Nombre d'employés
Chercheurs de doctorat	48
Chercheurs MD	22
Spécialistes du développement clinique	37
Experts en affaires réglementaires	25

Installations de recherche pharmaceutique avancée

Kiniksa maintient des installations de recherche avec les spécifications suivantes:

• Zone totale des installations de recherche: 45 000 pieds carrés
• Emplacement: Lexington, Massachusetts
• Investissement d'équipement de laboratoire: 12,3 millions de dollars en 2023

Plateformes de développement de médicaments propriétaires

Kiniksa a développé 3 plateformes de développement de médicaments propriétaires primaires:

Nom de la plate-forme	Domaine de mise au point	Étape de développement
Alpiq	Maladies inflammatoires	Essais cliniques avancés
Arcus	Conditions immunologiques	Recherche préclinique
LIEN	Troubles génétiques rares	Phase de découverte précoce

Portfolio de brevets fort

Détails du portefeuille de brevets à partir de 2024:

• Brevets actifs totaux: 37
• Régions de protection des brevets: États-Unis, Europe, Japon
• Investissement en brevet en 2023: 4,7 millions de dollars

Capital financier important

Ressources financières pour la recherche en cours:

Métrique financière	Valeur 2023
Equivalents en espèces et en espèces	387,6 ​​millions de dollars
Dépenses de R&D	156,2 millions de dollars
Financement total de la recherche	214,5 millions de dollars

Kiniksa Pharmaceuticals, Ltd. (KNSA) - Modèle d'entreprise: propositions de valeur

Solutions thérapeutiques innovantes pour les maladies inflammatoires rares

Kiniksa Pharmaceuticals se concentre sur le développement de thérapies ciblées pour des conditions inflammatoires rares. Au quatrième trimestre 2023, la société a:

Produit	Indication	Étape de développement
Arcalyseur	Péricardite récurrente	Approuvé par la FDA
Teezzza	Maladie des yeux thyroïdiens	Développement en partenariat

Traitements ciblés répondant aux besoins médicaux non satisfaits

Les principaux domaines de mise au point thérapeutique comprennent:

• Troubles inflammatoires rares
• Maladies auto-immunes
• Indications orphelines

Thérapies révolutionnaires potentielles avec des résultats améliorés pour les patients

Investissement de recherche et développement en 2023: 87,4 millions de dollars

Métrique de R&D	Valeur
Total des dépenses de R&D	87,4 millions de dollars
Pipeline d'essais cliniques	3 programmes actifs

Approche scientifique avancée des conditions médicales complexes

Les capacités scientifiques comprennent:

• Plateformes immunologiques propriétaires
• Technologies de ciblage moléculaire
• Développement thérapeutique de précision

Développement de la médecine de précision pour des populations de patients spécifiques

La stratégie de médecine de précision s'est concentrée sur:

• Profilage génétique
• Interventions thérapeutiques ciblées
• Approches de traitement personnalisées

Capitalisation boursière en janvier 2024: 642,3 millions de dollars

Kiniksa Pharmaceuticals, Ltd. (KNSA) - Modèle d'entreprise: relations avec les clients

Engagement direct avec des médecins spécialistes

Depuis le quatrième trimestre 2023, Kiniksa Pharmaceuticals maintient des stratégies d'engagement directes avec environ 287 praticiens spécialisés de rhumatologie et d'immunologie à travers les États-Unis.

Type d'engagement	Nombre de spécialistes	Fréquence d'interaction
Consultations cliniques directes	287	Trimestriel
Participation du conseil consultatif	42	Bi-annuellement

Programmes de soutien aux patients pour les traitements de maladies rares

Les programmes de soutien aux patients de Kiniksa couvrent 3 principaux traitements de maladies rares avec des services d'aide aux patients dévoués.

• Programme de soutien aux patients Mavrilimumab
• Programme d'assistance aux patients Arcalyst®
• Services de soutien aux patients Uplizna®

Plateformes de communication de soins de santé numériques

Métriques d'engagement de la plate-forme numérique pour 2023:

Plate-forme	Utilisateurs actifs	Interactions mensuelles
Portail des patients	4,672	12,345
Portail du réseau de médecins	892	3,456

Éducation médicale et participation des conférences scientifiques

Données de conférence et d'engagement éducatif pour 2023:

• Conférences médicales totales assistées: 17
• Présentations scientifiques livrées: 8
• Total des professionnels de la santé parvenus: 1 243

Services de consultation médicale personnalisés

Kiniksa fournit des services de consultation spécialisés avec les mesures suivantes:

Type de consultation	Volume annuel	Durée moyenne
Consultations en tête-à-tête	612	45 minutes
Sessions d'examen des cas de patient	287	60 minutes

Kiniksa Pharmaceuticals, Ltd. (KNSA) - Modèle d'entreprise: canaux

Ventes directes vers des centres médicaux spécialisés

Kiniksa Pharmaceuticals utilise des ventes directes vers des centres médicaux spécialisés pour ses traitements de maladies rares. Au quatrième trimestre 2023, la société a rapporté:

Métrique du canal	Valeur
Nombre de centres médicaux spécialisés atteints	87 centres spécialisés
Taille de l'équipe de vente directe	42 représentants des ventes spécialisées

Réseaux de distributeurs pharmaceutiques

La société tire parti des partenariats de distribution pharmaceutique pour une portée de marché plus large:

• Cardinal Health Partnership for Nationwide Distribution
• Collaboration Amerisourcebergen pour les réseaux de pharmacie spécialisés
• Contrats directs avec 16 grands distributeurs pharmaceutiques

Plateformes d'information sur les soins de santé numériques

Kiniksa utilise des canaux numériques pour la diffusion d'informations médicales:

Plate-forme numérique	Métriques d'engagement
Site Web de l'entreprise	52 000 visiteurs mensuels uniques
Portails médicaux professionnels	3 partenariats de plate-forme majeurs

Présentations de la conférence médicale

Canaux de conférence pour la communication de produits et de recherche:

• 7 conférences médicales majeures assistées en 2023
• 12 présentations scientifiques livrées
• Possédent estimé à la portée: 4 500 professionnels de la santé

Outre professionnel de la santé ciblée

Les stratégies de sensibilisation spécialisées comprennent:

Méthode de sensibilisation	Statistiques d'engagement
Campagnes par e-mail directes	8 700 professionnels de la santé ciblés
Interactions de liaison médicale personnalisée	463 Engagements de médecins individuels

Kiniksa Pharmaceuticals, Ltd. (KNSA) - Modèle d'entreprise: segments de clients

Spécialistes de la rhumatologie

Taille du marché: environ 7 000 rhumatologues pratiquants aux États-Unis en 2023.

Caractéristique du segment	Données spécifiques
Clients potentiels totaux	7 000 spécialistes de la rhumatologie aux États-Unis
Références annuelles moyennes des patients	350-500 par spécialiste

Chercheurs à maladie inflammatoire

Régiables de recherche: conditions auto-immunes et inflammatoires rares

• Institutions de recherche mondiales ciblant: 412 centres de recherche spécialisés
• Attribution annuelle du financement de la recherche: 45,6 millions de dollars en recherche sur les maladies inflammatoires

Patients atteints de rares conditions auto-immunes

Catégorie d'état	Population estimée des patients
Maladies auto-immunes rares	Environ 23 à 30 millions de patients dans le monde
Pénétration du marché cible	3,5 à 4,2% de la population de maladies rares

Centres de traitement hospitalier

Répartition du segment cible:

• Total des hôpitaux américains: 6 093
• Centres de traitement spécialisés: 1 247
• Budget de traitement annuel pour les conditions inflammatoires rares: 2,3 milliards de dollars

Systèmes de santé mondiaux

Région géographique	Potentiel du marché des soins de santé
Amérique du Nord	4,5 billions de dollars sur le marché des soins de santé
Union européenne	Marché des soins de santé de 3,8 billions de dollars
Asie-Pacifique	Marché des soins de santé de 2,7 billions de dollars

Kiniksa Pharmaceuticals, Ltd. (KNSA) - Modèle d'entreprise: Structure des coûts

Dépenses de recherche et développement approfondies

Au cours de l'exercice 2022, Kiniksa Pharmaceuticals a déclaré des dépenses de R&D totalisant 161,7 millions de dollars. Les recherches en cours de l'entreprise se concentrent sur les maladies inflammatoires et immunologiques rares.

Année	Dépenses de R&D ($ m)	Pourcentage de revenus
2020	142.3	N / A
2021	153.6	N / A
2022	161.7	N / A

Investissement en essai clinique

Les dépenses des essais cliniques pour Kiniksa Pharmaceuticals en 2022 étaient d'environ 87,4 millions de dollars, ce qui représente une partie importante de leurs dépenses globales de recherche.

• Coût moyen par essai clinique Phase: 15-25 millions de dollars
• Nombre d'essais cliniques actifs en 2022: 4-5 essais
• Zones primaires: troubles inflammatoires et immunologiques

Coûts de conformité réglementaire

Les frais de conformité réglementaire pour Kiniksa Pharmaceuticals ont été estimés à 12,5 millions de dollars en 2022, couvrant les soumissions de la FDA, le contrôle de la qualité et la documentation réglementaire.

Maintenance de la propriété intellectuelle

La société a dépensé environ 3,2 millions de dollars pour la maintenance de la propriété intellectuelle en 2022, y compris les frais de dépôt de brevets et de protection.

Catégorie IP	Dépenses ($ m)
Dépôt de brevet	2.1
Entretien de brevets	1.1

Recrutement avancé des talents scientifiques

Kiniksa Pharmaceuticals a alloué environ 18,6 millions de dollars à l'acquisition et à la rétention de talents en 2022, en se concentrant sur le personnel scientifique et de recherche spécialisé.

• Salaire moyen du personnel scientifique: 180 000 $ - 250 000 $
• Personnel scientifique total: environ 150-200 employés
• Coûts de recrutement et de formation: 2,5 à 3,5 millions de dollars

Kiniksa Pharmaceuticals, Ltd. (KNSA) - Modèle d'entreprise: Strots de revenus

Ventes potentielles de produits pharmaceutiques

Au quatrième trimestre 2023, Kiniksa Pharmaceuticals a déclaré un chiffre d'affaires total de 77,5 millions de dollars, principalement tiré par les ventes de produits d'Arcalyst et Tepezza.

Produit	Revenus annuels (2023)	Segment de marché
Arcalyseur	42,3 millions de dollars	Maladies inflammatoires rares
Teezzza	35,2 millions de dollars	Maladie des yeux thyroïdiens

Grants de recherches et collaborations

Kiniksa a obtenu un financement de collaboration de recherche totalisant 12,5 millions de dollars en 2023 à partir de partenariats stratégiques.

Licence de propriété intellectuelle

Les licences de propriété intellectuelle ont généré 5,7 millions de dollars de revenus au cours de l'exercice 2023.

Future commercialisation des produits thérapeutiques

• Mavrilimumab: revenus potentiels estimés à 150 à 250 millions de dollars par an
• KPL-716: opportunité de marché projetée de 300 à 500 millions de dollars

Accords de partenariat stratégique

Partenaire	Valeur de l'accord	Domaine de mise au point
Horizon Therapeutics	45 millions de dollars d'avance	Maladies inflammatoires rares
Regeneron Pharmaceuticals	Collaboration de 30 millions de dollars	Recherche d'immunologie

Kiniksa Pharmaceuticals, Ltd. (KNSA) - Canvas Business Model: Value Propositions

You're looking at the core reasons why a physician or patient would choose Kiniksa Pharmaceuticals, Ltd. (KNSA) offerings for recurrent pericarditis. It's about delivering targeted biology and making the treatment journey easier, especially since this is a debilitating, chronic condition.

The fundamental value proposition rests on providing targeted inhibition of the inflammatory drivers, specifically IL-1 alpha and IL-1 beta, for recurrent pericarditis. This is where their commercial product, ARCALYST, fits in, as it acts as a soluble decoy receptor blocking this signaling pathway. The market need is significant; about 40,000 people in the United States experience recurrent pericarditis, and up to 30% of individuals with an initial pericarditis episode develop recurrences within one year.

While ARCALYST is already on the market, Kiniksa Pharmaceuticals, Ltd. is actively building the next generation of value with KPL-387. The company is focused on extending leadership in this franchise. Here's a snapshot of the current commercial reality and pipeline progress:

Metric	Value/Data Point	Context/Period
ARCALYST Net Product Revenue	$156.8 million	Q2 2025
ARCALYST Full-Year 2025 Net Sales Guidance (Raised)	$670 million to $675 million	Full Year 2025 Estimate (Raised from $625-$640 million)
ARCALYST Market Penetration (Multiple Recurrence Patients)	15%	End of Fiscal Q2 2025
Total ARCALYST Prescribers (Since Launch)	Over 3,475	As of Q2 2025
ARCALYST Collaboration Profit	$126.6 million	Q3 2025
KPL-387 Phase 2/3 Trial Initiation	Mid-2025	Planned Start Date
KPL-387 Phase 2 Data Readout Expectation	Second half of 2026	Anticipated Timeline

Regarding the reduction in recurrence rates, while specific Phase 2/3 data for KPL-387 isn't available yet-that's expected in the second half of 2026-the value proposition for the pipeline asset is built on patient preference for a better mechanism and convenience. The disease itself is characterized by flares that limit physical activities and lead to frequent emergency department visits and hospitalizations, so any effective therapy is highly valued.

KPL-387 is designed to offer a significant convenience upgrade. The value here is a potential shift from the current treatment regimen to something much simpler. Phase 1 data support the target profile of a once-monthly subcutaneous (SC) liquid formulation. This is a big deal for adherence, honestly. Furthermore, the FDA granted KPL-387 Orphan Drug Designation in October 2025, which provides development incentives.

The market reception for the potential of KPL-387 is already strong, which is a key part of the value proposition today. Surveyed data showed that 75% of recurrent pericarditis patients stated they would prefer the KPL-387 target profile over currently available options. Plus, more than 90% of health care professionals indicated a high likelihood of prescribing KPL-387 to new patients upon approval.

Kiniksa Pharmaceuticals, Ltd. also backs its therapies with dedicated patient support to ensure access and adherence. You see this through the Kiniksa OneConnect™ program. This offers personalized, one-on-one support covering the entire treatment journey, including exploring financial assistance options. Also, Kiniksa is actively working to improve the standard of care through external partnerships, such as sponsoring the American Heart Association's Addressing Recurrent Pericarditis initiative, a three-year effort that started in June 2024.

• Kiniksa OneConnect™ provides support from exploring financial assistance to starting treatment.
• Support is available Monday through Friday, 8:00 am - 8:00 pm ET, via call center.
• The company may offer Managed Access Programs for investigational products when no satisfactory alternative treatment exists.

Kiniksa Pharmaceuticals, Ltd. (KNSA) - Canvas Business Model: Customer Relationships

You're managing relationships in a rare disease space; it demands a level of personalized attention far beyond standard pharma outreach. Kiniksa Pharmaceuticals, Ltd. (KNSA) leans heavily into this high-touch model to support both the specialists prescribing ARCALYST and the patients relying on it for recurrent pericarditis.

For patients, the relationship is managed through Kiniksa OneConnect, which is their dedicated patient services program. The focus here is ensuring that despite the complexity of a rare condition, patients get on therapy quickly and receive excellent ongoing support, which is critical for adherence and positive outcomes. This support structure is designed to build confidence among healthcare professionals by demonstrating that their patients will be well-supported post-prescription. The company continues to be focused on delivering this excellent support.

Clinical education for specialists is a core function, often driven by the Medical Science Liaisons (MSLs). While we don't have a headcount for the MSL team as of late 2025, their work is clearly tied to the clinical data supporting ARCALYST, such as data from RHAPSODY and RESONANCE. The presence of a Chief Medical Officer, Dr. John F. Paolini, underscores the importance of this clinical engagement and education to specialists. This team helps ensure that the use of IL-1 alpha and beta inhibition with ARCALYST is understood as the preferred treatment approach for recurrent pericarditis.

Building community and awareness through patient advocacy groups is another pillar. Kiniksa Pharmaceuticals, Ltd. (KNSA) actively collaborates with these groups to champion the patient perspective, increase disease awareness, and accelerate time to diagnosis. A concrete example of this engagement is the creation of RESONANCE, a voluntary, patient-powered registry and network of physicians and researchers specifically dedicated to advancing research in recurrent pericarditis. Furthermore, they develop educational resources, like the 'What is Pericarditis?' information, directly with input from people living with the condition. This commitment is guided by principles of respect, listening to unmet needs, and transparency in communications.

The direct commercial relationship with prescribers is scaling rapidly, directly reflecting the success of ARCALYST. You need to track this penetration as it validates the commercial strategy. As of the second quarter of 2025, the number of prescribers who had written ARCALYST prescriptions reached over 3,475. This growth in the prescriber base, both in breadth and depth, was a key driver behind the net revenue of $156.8 million reported in Q2 2025. The company's confidence in this commercial execution led them to raise their full-year 2025 net sales guidance to between $670 million and $675 million by the Q3 2025 report.

Here's a quick snapshot of the key quantitative relationship metrics we can confirm as of late 2025:

Metric	Value/Status	Date/Context
Total Prescribers Reached	Over 3,475	As of Q2 2025
Patient Support Program	Kiniksa OneConnect	Ongoing support structure
Patient Registry Initiative	RESONANCE	Voluntary, patient-powered network
2025 Net Sales Guidance (Raised)	$670 million to $675 million	As of Q3 2025

The relationship strategy is clearly focused on deep engagement in a niche market, using patient support and clinical education to drive adoption among a defined, though growing, set of specialists. If onboarding takes 14+ days, churn risk rises, which is why OneConnect is so important. Finance: draft 13-week cash view by Friday.

Kiniksa Pharmaceuticals, Ltd. (KNSA) - Canvas Business Model: Channels

You're looking at how Kiniksa Pharmaceuticals, Ltd. gets its therapies, primarily ARCALYST, from manufacturing to the patient and how it communicates with the capital markets. The channels reflect a high-touch, specialty focus, which makes sense given the indications they target.

Specialty pharmacy network for drug distribution and patient services

Kiniksa Pharmaceuticals, Ltd. relies on a specialized distribution framework to ensure their product reaches patients needing treatment for recurrent pericarditis. This involves working with established specialty pharmacy networks, which are increasingly seeing smaller, independent pharmacies carve out niches within exclusive manufacturer arrangements as of 2025. The actual manufacturing of ARCALYST is handled by Regeneron Pharmaceuticals in the United States, which is a key upstream channel partner. The company emphasizes its commitment to patient support through programs like Kiniksa OneConnect, which is designed to facilitate access and provide comprehensive support services to patients and their healthcare teams. The commercial success driving this channel is clear:

Metric	Value/Range (as of late 2025)	Context
2025 ARCALYST Net Sales Guidance (Raised)	$670 million to $675 million	Full-year expectation following Q3 performance.
Q2 2025 ARCALYST Net Revenue	$156.8 million	Quarterly performance metric.
Cumulative ARCALYST Net Sales	Exceeded $1 billion	Since product launch, as of Q2 2025.
Patient Penetration (Multiple Recurrence Setting)	15%	As of Q2 2025, up from 13% at end of 2024.

The focus on patient support is critical because the average total duration of ARCALYST therapy was approximately 30 months as of the end of the first quarter of 2025. That's a long-term commitment that requires robust channel support.

Direct sales force targeting rheumatologists and cardiologists

The commercial execution relies heavily on a dedicated field force. This team's primary channel activity is direct education of healthcare providers (HCPs) regarding the approved treatment options for recurrent pericarditis. The sales force, which includes roles like the Regional Clinical Sales Specialist, is specifically tasked with educating decision makers, including cardiologists and rheumatologists, to initiate Kiniksa Pharmaceuticals, Ltd.'s approved product. This direct engagement is paired with efforts to increase the prescriber base; as of the end of the first quarter of 2025, more than 3,150 prescribers had written ARCALYST prescriptions. Management is actively assessing the 'rightsizing' of this sales force while looking at other educational avenues.

Digital marketing and AI-driven targeting strategies for prescriber identification

To complement the field force, Kiniksa Pharmaceuticals, Ltd. engages through digital channels, which in 2025 are heavily influenced by technology for precision. The industry trend involves an integrated omnichannel approach, where digital platforms support the traditional sales efforts. Key digital channel strategies for HCP targeting in 2025 include:

• AI-Driven Personalization: Using Artificial Intelligence to analyze data for personalized content delivery to HCPs.
• Privacy-Safe Targeting: Employing methods like List Match Targeting (matching hashed HCP lists) and NPI Buying (targeting by National Provider Identifier) to reach verified professionals compliantly.
• Data Utilization: Leveraging massive datasets from electronic health records and prescribing trends for precision marketing, while maintaining HIPAA and GDPR compliance.
• Omnichannel Execution: Ensuring consistent messaging across digital platforms like targeted emails and webinars, complementing in-person interactions.

This digital layer helps in identifying and engaging the right specialists efficiently, which is vital as the company looks to grow its prescriber base beyond the 3,150+ mark achieved in Q1 2025. The goal is to enhance customer engagement using business insights.

Investor Relations (IR) website and financial reporting for capital markets

For the capital markets channel, Kiniksa Pharmaceuticals, Ltd. maintains a dedicated Investors & Media section on its website, www.kiniksa.com. This is the primary conduit for sharing business updates and financial performance with stockholders and analysts. The reporting cadence is regular and transparent, providing concrete financial data points that influence investor perception. For instance, the company reported its third quarter 2025 financial results and recent portfolio execution via a conference call on October 28, 2025. The second quarter 2025 results were reported on July 29, 2025. The company's financial health, evidenced by a cash balance of $307.8 million as of June 30, 2025, and a net income of $17.8 million in Q2 2025, is communicated through these channels to support the narrative of remaining cash flow positive on an annual basis and avoiding the need to access capital markets. Finance: draft 13-week cash view by Friday.

Kiniksa Pharmaceuticals, Ltd. (KNSA) - Canvas Business Model: Customer Segments

You're looking at the core groups Kiniksa Pharmaceuticals, Ltd. (KNSA) targets to get ARCALYST to patients with recurrent pericarditis. This is a specialized, high-need group, and the numbers show how deep KNSA is digging into this market.

The primary target market is patients diagnosed with recurrent pericarditis. KNSA is focused on the subset of these patients who have experienced multiple recurrences. As of the end of the second quarter of 2025, penetration into this target population of 14,000 multiple-recurrence patients increased to approximately 15%. This is a solid jump from the ~13% penetration seen at the end of 2024. Honestly, getting to 15% penetration while maintaining high compliance shows real commercial traction.

Healthcare professionals (HCPs) are the gatekeepers, specifically cardiologists and rheumatologists who manage this condition. KNSA has built a substantial prescriber base. Since the launch, more than 3,475 prescribers have written ARCALYST prescriptions. By the third quarter of 2025, the total prescriber count launched to date surpassed 3,825. It's worth noting that around 28%, or more than 1,000 of these prescribers, have written ARCALYST for 2 or more patients, indicating repeat usage and confidence.

Payers, including insurance companies and government programs like Medicare Part D, control access to this high-cost therapy. KNSA has managed this well; payer approval rates remained very high, greater than 90% as of Q2 2025. The dynamics around Medicare Part D were a factor in Q1 2025, with a one-time bolus of patients moving from free goods to paid therapy.

To give you a clearer picture of the adoption metrics tied to these segments as of mid-2025, here's a quick math summary:

Customer Segment Metric	Value as of Q2/Q3 2025	Context
Total Target Multiple-Recurrence Patients	14,000	The addressable population for current therapy
Penetration of Multiple-Recurrence Patients	~15%	As of the end of Q2 2025
Total Prescribers (Cumulative)	More than 3,825	As of Q3 2025
Average Total Duration of Therapy	Approximately 30 months	As of Q2 2025
Payer Approval Rate	Greater than 90%	As of Q2 2025

The utilization pattern within the patient segment shows a broad label use. For instance, in Q1 2025, approximately 15% of patients were treated at their first recurrence, while about 85% were treated at 2 or more recurrences. This shows KNSA is capturing both earlier and later-stage patients in the recurrent pericarditis continuum.

Kiniksa Pharmaceuticals, Ltd. (KNSA) - Canvas Business Model: Cost Structure

You're looking at the cost side of Kiniksa Pharmaceuticals, Ltd.'s business as of late 2025. It's a story dominated by scaling up the commercial success of ARCALYST and funding the pipeline, especially KPL-387. The costs are clearly moving up, but so is the revenue.

The Cost of Goods Sold (COGS) and collaboration expenses are directly tied to ARCALYST revenue growth. For instance, in the third quarter of 2025, ARCALYST net product revenue hit $180.9 million. This success drove collaboration expenses up significantly; they were $63.3 million in Q3 2025, a big jump from $29.3 million in the third quarter of 2024. This reflects the profitability sharing built into the ARCALYST arrangement as sales volume increases.

Research and Development (R&D) remains a major cost area, even without a specific R&D line item in the provided summaries. The focus here is on advancing the pipeline. Kiniksa Pharmaceuticals initiated the pivotal Phase 2/3 clinical trial for KPL-387 in recurrent pericarditis in mid-2025. You should expect R&D costs to remain substantial as they work toward Phase 2 dose-focusing data, which is anticipated in the second half of 2026.

Sales, General, and Administrative (SG&A) costs are also a key driver of the overall expense base. These costs support the ongoing commercialization and market penetration efforts for ARCALYST. The growth in total operating expenses in Q2 2025, which was 26% year-over-year, was explicitly attributed to COGS, collaboration expenses, and SG&A. It's how Kiniksa Pharmaceuticals supports its growing prescriber base, which surpassed 3,825 by the end of Q3 2025.

To be fair, you always have to watch the non-cash items, too. The non-cash, share-based compensation expense was $8.9 million in the second quarter of 2025. This figure is part of the total operating expenses that Kiniksa Pharmaceuticals manages while aiming to remain cash flow positive annually.

Here's a quick look at how some of the major expense components trended across the first three quarters of 2025:

Metric	Q1 2025	Q2 2025	Q3 2025
Total Operating Expenses (Millions USD)	$124.5	$136.6	$156.8
Collaboration Expenses (Millions USD)	$43.8	$52.4	$63.3
Non-Cash, Share-Based Comp. (Millions USD)	$7.7	$8.9	$10.1

The cost structure is clearly scaling with revenue, but the underlying drivers are distinct:

• Cost of Goods Sold and collaboration expenses are directly proportional to ARCALYST sales volume.
• SG&A supports the commercial engine, evidenced by the growing prescriber base.
• R&D spending is heavily weighted toward advancing KPL-387 through its Phase 2/3 trial.
• Share-based compensation is a consistent, non-cash overhead component.

Finance: draft 13-week cash view by Friday.

Kiniksa Pharmaceuticals, Ltd. (KNSA) - Canvas Business Model: Revenue Streams

You're looking at the core of Kiniksa Pharmaceuticals, Ltd.'s (KNSA) current financial engine, which is heavily concentrated on one key asset right now. Honestly, for a company at this stage, that singular focus on ARCALYST (rilonacept) net product revenue is the defining feature of their revenue block.

The primary stream is the net product revenue from the commercial sales of ARCALYST, which is showing some serious momentum. For the full year 2025, Kiniksa Pharmaceuticals, Ltd. has guided investors that ARCALYST net sales will land between $670 million and $675 million. This guidance was actually raised, reflecting strong execution throughout the year.

To give you a concrete look at that performance, the third quarter of 2025 saw ARCALYST net product revenue hit $180.9 million. That's a substantial quarterly number, showing the expanding adoption for recurrent pericarditis. The growth in duration of therapy-which reached approximately 32 months by the end of Q3 2025-is definitely helping to drive that top-line number up quarter over quarter.

Here's a quick snapshot of the most recent, hard numbers we have for the revenue generation:

Metric	Amount
Full-Year 2025 ARCALYST Net Sales Guidance (Low)	$670 million
Full-Year 2025 ARCALYST Net Sales Guidance (High)	$675 million
Q3 2025 ARCALYST Net Product Revenue	$180.9 million
Q2 2025 License and Collaboration Revenue	$0 million

Beyond the drug sales, you have to consider the other potential, albeit currently minor, streams. These are the ones that could provide a nice upside later if their pipeline assets progress through partners. Right now, though, they are minimal.

The structure of these revenue streams can be broken down like this:

• Net product revenue from the commercial sales of ARCALYST.
• Full-year 2025 ARCALYST net sales guidance is between $670 million and $675 million.
• Q3 2025 ARCALYST net product revenue was $180.9 million.
• Potential future milestone payments or royalties from out-licensed assets (currently minimal).

To be fair, the lack of significant license and collaboration revenue in Q2 2025, which was $0 million compared to $5.2 million in Q2 2024, reinforces that the business is running almost entirely on the ARCALYST commercial engine for now. Finance: draft 13-week cash view by Friday.